The business research & consulting firm Frost & Sullivan has announced the selection of Exiqon as the recipient of its 2008 Growth Strategy Leadership Award in the molecular diagnostic market. Exiqon was selected for this award for the company’s acquisition of Oncotech, a market leader in the field of in vitro therapy selection testing for cancer. The acquisition of Oncotech allowed the two companies to combine resources to become a leading supplier of molecular diagnostic tests based on proprietary miRNA biomarkers.
“Combining the two companies has allowed Exiqon to master a number of the most significant challenges in building a platform for its future molecular diagnostic business in the US,“ says CEO Lars Kongsbak.
Exiqon has already established itself as one of the market’s leading providers of research products for gene expression analysis based on the LNA™ technology.
